Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Patrick J. Duriez"'
Autor:
Osman Dadas, Joel D. Allen, Sarah L. Buchan, Jinny Kim, H. T. Claude Chan, C. Ian Mockridge, Patrick J. Duriez, Anne Rogel, Max Crispin, Aymen Al-Shamkhani
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionT cell expressed CD27 provides costimulation upon binding to inducible membrane expressed trimeric CD70 and is required for protective CD8 T cell responses. CD27 agonists could therefore be used to bolster cellular vaccines and anti-tumou
Externí odkaz:
https://doaj.org/article/1b431c0777aa4151a8bb65c2e1304139
Autor:
Denise S. M. Boulanger, Leon R. Douglas, Patrick J. Duriez, Yoyel Kang, Neil Dalchau, Edd James, Tim Elliott
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Tapasin, a component of the major histocompatibility complex (MHC) I peptide loading complex, edits the repertoire of peptides that is presented at the cell surface by MHC I and thereby plays a key role in shaping the hierarchy of CD8+ T-cell respons
Externí odkaz:
https://doaj.org/article/2f1f27988b954152a0776d183a046b30
Autor:
Xiaojie Yu, Sonya James, James H. Felce, Blanka Kellermayer, David A. Johnston, H. T. Claude Chan, Christine A. Penfold, Jinny Kim, Tatyana Inzhelevskaya, C. Ian Mockridge, Yasunori Watanabe, Max Crispin, Ruth R. French, Patrick J. Duriez, Leon R. Douglas, Martin J. Glennie, Mark S. Cragg
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-15 (2021)
Yu et al examined a panel of both experimental and clinically-relevant TNF agonists in order to advance our understanding of the mechanisms underlying their varying activities and anti-tumor responses. They demonstrated that agonists with greater act
Externí odkaz:
https://doaj.org/article/497b996aa1574d6a946f5ee6787fec3f
Autor:
Beatriz Valle-Argos, Giorgia Chiodin, Dean J. Bryant, Joe Taylor, Elizabeth Lemm, Patrick J. Duriez, Philip J. Rock, Jonathan C. Strefford, Francesco Forconi, Richard W. Burack, Graham Packham, Freda K. Stevenson
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract In follicular lymphoma (FL), surface immunoglobulin (sIg) carries mandatory N-glycosylation sites in the variable regions, inserted during somatic hypermutation. These glycosylation sites are tumor-specific, indicating a critical function in
Externí odkaz:
https://doaj.org/article/0f9b4c5e32fc4b8ab9e5de05992b58d9
Autor:
Sergio Regufe da Mota, Sarah Bailey, Rosemary A. Strivens, Annette L. Hayden, Leon R. Douglas, Patrick J. Duriez, M. Teresa Borrello, Hanae Benelkebir, A. Ganesan, Graham Packham, Simon J. Crabb
Publikováno v:
Cancer Cell International, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background Castrate resistant prostate cancer (CRPC) is often driven by constitutively active forms of the androgen receptor such as the V7 splice variant (AR-V7) and commonly becomes resistant to established hormonal therapy strategies such
Externí odkaz:
https://doaj.org/article/4ce9ec32f7714957826dd1a3a38d81ad
Autor:
Metin Cetin, Gorkem Odabas, Leon R. Douglas, Patrick J. Duriez, Pelin Balcik-Ercin, Irem Yalim-Camci, Abdulkadir Emre Sayan, Tamer Yagci
Publikováno v:
Cells, Vol 8, Iss 3, p 210 (2019)
Background: Hepatocellular carcinoma (HCC) is a common and deadly cancer; however, very little improvement has been made towards its diagnosis and prognosis. The expression and functional contribution of the receptor tyrosine kinase ROR1 have not bee
Externí odkaz:
https://doaj.org/article/4b1bb8f973e04f86849cd96b386b7819
Autor:
Emma M. Creagh, Gabriela Brumatti, Clare Sheridan, Patrick J. Duriez, Rebecca C. Taylor, Sean P. Cullen, Colin Adrain, Seamus J. Martin
Publikováno v:
PLoS ONE, Vol 4, Iss 3 (2009)
Externí odkaz:
https://doaj.org/article/a27ece0e923643e0b3a0f8c3bf9eeb2f
Autor:
Stephen A. Beers, Mark S. Cragg, Martin J. Glennie, Jessica L. Teeling, Diego Gomez-Nicola, Patrick J. Duriez, Andrew J. Steele, Francesco Forconi, Ian Tracy, Salome Murinello, Kerry L. Cox, Alexander Earley, Rena Liu, Khiyam Hussain, Lang Dou, Lekh N. Dahal
This file contains supplementary data showing phenotypic/cytokine/chemokine changes in immune cell population following stimulation/tumour inoculation. The data also demonstrate that monocyte and neutrophil are not required for mAb mediated deletion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b512d898dbe1ff26b9592470f3760de
https://doi.org/10.1158/0008-5472.22414716
https://doi.org/10.1158/0008-5472.22414716
Autor:
Stephen A. Beers, Mark S. Cragg, Martin J. Glennie, Jessica L. Teeling, Diego Gomez-Nicola, Patrick J. Duriez, Andrew J. Steele, Francesco Forconi, Ian Tracy, Salome Murinello, Kerry L. Cox, Alexander Earley, Rena Liu, Khiyam Hussain, Lang Dou, Lekh N. Dahal
Tumors routinely attract and co-opt macrophages to promote their growth, angiogenesis, and metastasis. Macrophages are also the key effector cell for mAb therapies. Here we report that the tumor microenvironment creates an immunosuppressive signature
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb3b7826c615c5fc5826089fe7d7823c
https://doi.org/10.1158/0008-5472.c.6509061.v1
https://doi.org/10.1158/0008-5472.c.6509061.v1
Autor:
Joseph R. Stephenson Clarke, Leon R. Douglas, Patrick J. Duriez, Dimitrios-Ilias Balourdas, Andreas C. Joerger, Raniya Khadiullina, Emil Bulatov, Matthias G. J. Baud
Publikováno v:
ACS pharmacologytranslational science. 5(11)
The tumor suppressor protein p53 is inactivated in the majority of human cancers and remains a prime target for developing new drugs to reactivate its tumor suppressing activity for anticancer therapies. The oncogenic p53 mutant Y220C accounts for ap